Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants

        Print
| Source: Veloxis Pharmaceuticals A/S
multilang-release

Company Announcement no. 20/2014

 

To: NASDAQ OMX Copenhagen A/S                             Hørsholm, Denmark, 1 September 2014

  

 

Warrant Programme - Veloxis Pharmaceuticals A/S issues new shares in connection with exercise of warrants

 

Veloxis Pharmaceuticals A/S announces that the company's capital has been increased by 470,031 new shares with a nominal value of DKK 0.10 each corresponding to nominal DKK 47,003.10 as a consequence of the exercise of warrants by former and current employees and members of the board of directors granted under the company's warrant program.

 

Proceeds to Veloxis Pharmaceuticals A/S from the capital increase amounts to DKK 304,004.

 

The subscription price for the new shares per share of nominal DKK 0.10 is as follows:

 

For 256,639 shares, the price per share is DKK. 0.35. For 54,167 shares, the price per share is DKK 0.58. For 9,225 shares, the price per share is DKK 0.95. For 150,000 shares, the price per share is DKK 1.16.

 

The new shares will be listed on NASDAQ OMX Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 166,299,731.40 divided into shares of DKK 0.10 each.

 

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S. The new shares gives rights to dividend and other rights from the time of the warrant holder's exercise notice.

 

The content of this announcement has no impact on the company’s financial outlook for 2014.

 

For more information, please contact:

 

Veloxis Pharmaceuticals A/S

Bill Polvino                                           Johnny Stilou

President & CEO                                   EVP, Chief Financial Officer

Mobile: +1 917 647 9107                      Mobile: +45 21 227 227

Email: wjp@veloxis.com                       Email: jst@veloxis.com

  

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. The company’s lead product candidate is Envarsus® XR for immunosuppression, specifically organ transplantation. Veloxis’ unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs.  Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Salix, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.